Pharmaceutical Companies in Spain

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: • Development of tailor-made baculovirus vectors optimized for industrial production. • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®. • Supply of recombinant proteins produced in CrisBio® through license agreements. • Development of proprietary portfolios. Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.

Content Ed Net provides communication services to medical affairs and marketing teams in pharmaceutical companies around the world Many local factors influence how communications are structured, sourced and managed - culture, language, regulatory environment, and educational need. Our goal is to help you create, publish, buy and disseminate the content needed to address these factors - more efficiently, more reliably and with reduced risk. We do this through our teams of experienced medical publishing professionals based around the world. Aligned to our clients with 41 offices in 31 countries, we specialise in global reach and local delivery. We have local staff delivering cost-effectively, with simpler logistics, and providing tax-compliant local invoicing. We offer solutions in three areas: Reprints & Rights Providing Copyright Compliant Materials to Support your Educational and Marketing Programs • Reprints • Translations • Permissions Medical Writing With more than 200 years of publication planning and editorial experience, our team is on hand to help • Planning • Publications • Symposia & Meetings Local Communications Engaging with Health Care Professionals & Patients locally • Physician Engagement • Local Publications • Advertising & Media

At Devon Labs, we work to solve patients' unmet medical and care needs, improving their quality of life and improving therapeutic outcomes. We achieve this by providing disease management tools to the caregiver and the physician, through new forms of personalised care and innovative therapies within the areas of pain and chronic disorders of the Central Nervous System (CNS).

Luda Partners is a neural network of pharmacies generating new sources of income and reducing shortages.

Trichome Pharma is a leading pharmaceutical company specialized in the cultivation, development, and commercialization of medicinal-grade cannabis and consumer healthcare products. We're on a mission to establish the next generation of alternative healthcare by unlocking the true potential of cannabis to enhance patient and consumer quality of life. Trichome Pharma leverages decades of knowledge and experience with best-in-class partners to deliver excellence across the entire cannabis value chain. Our activities include agronomic research, product innovation, brand development, market access and distribution, as well as cannabis education. Trichome Pharma's agricultural operations, consisting of organically-certified outdoor cultivation and low-touch greenhouse facilities, provide the perfect conditions for growing the best and highest quality cannabis available. Downstream, we're developing Spain's first family of wellness brands based on phytocannabinoids, targeting high-growth consumer healthcare niches.

Empresa Internacional fabricante de productos terapéuticos fitodermotricológicos, dermocosméticos, y con una especialidad llamada DERMOTRICOLOGIA registrada a nivel mundial, se basa en el previo diagnóstico de la piel y el cabello para poder aconsejar las aplicaciones de los productos más adecuados para cada anomalía. Somos único en nuestro sector, marcando diferencia con el resto de las demás firmas del mercado.